Nautilus Biotechnology (NAUT) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Nautilus Biotechnology (NAUT) is currently in the initial expansion and validation phase of its digital protein analysis system as it strives to bring its products to market. The technological foundation relies on a unique method of decoding biodata within US laboratories. The market trend shows an EV/EBITDA of 0.00, which is attributed to a lack of profitability and high R&D expenditures during the pre-commercial period.
Comprehensive metric breakdowns and analytics for nautilus.bio (NAUT)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Nautilus Biotechnology|NAUT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Nautilus Bio|NAUT - Company Debts|Debts to Book Capitalization NAUT|NAUT - Long-Term Debt Volume|Company Short-Term Debt Nautilus Biotechnology|Quick Liquidity Indicator nautilus.bio
- net income and valuation multiples indicators:
NAUT - Profit After Payment of Taxes|Projected Future Earnings Nautilus Biotechnology|NAUT - Market Cap to Earnings|Forward P/E Multiple Nautilus Bio|NAUT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NAUT|NAUT - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Nautilus Biotechnology|NAUT - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months nautilus.bio|NAUT - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Nautilus Biotechnology
Summary company analytics:Nautilus Biotechnology Inc NAUT
The multiple compares the total enterprise value, including debt, to operating profit before depreciation and amortization, allowing for an assessment of the real value of assets without the influence of the tax regime. For Nautilus Biotechnology (NAUT), which owns an automated protein analysis complex in Washington, this metric reflects the efficiency of capital expenditures in infrastructure, as clearly captured by the company's EV/EBITDA chart.
Analysis of competing companies
EV/EBITDA Multiple TEM (tempus.com)|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc (CRSP) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|10x Genomics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Intellia - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA wavelifesciences.com (WVE)|Enterprise Value to EBITDA Ratio MAZE|SION (Sionna Therapeutics, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA - Company Value to EBITDA|EV/EBITDA Multiple QURE (uniQure N.V.)|MGTX - Enterprise Value to EBITDA Ratio|REGENXBIO - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation SLDB (Solid Biosciences Inc)|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation PACB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|Company Value to EBITDA designtx.com DSGN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FDMT (4DMT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Company Value to EBITDA|Editas Medicine, Inc. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple silence-therapeutics.com (SLN)|PRQR (proqr.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Codexis (CDXS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|Enterprise Value to Operating Income Before Depreciation MGX (Metagenomi Therapeutics)|EV/EBITDA Multiple DTIL|EV/EBITDA Multiple generationbio.com (GBIO)|Boundless Bio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Exicure Inc. XCUR|IMNN: Enterprise Value to EBITDA Ratio|Phio Pharmaceuticals - Enterprise Value to Operating Income Before Depreciation Ratio|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC: Enterprise Value to Operating Income Before Depreciation|Regulus Therapeutics Inc. - EV/EBITDA Multiple|SYRS - EV/EBITDA Multiple|TBIO (Codex DNA) - Enterprise Value to EBITDA Ratio|TRACON Pharmaceuticals, Inc (TCON) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio UBX
